Abstracts tagged "Patient outcomes and tofacitinib"

Abstract Number: 500 • 2017 ACR/ARHP Annual Meeting
Low Patient Global Assessment Scores in Rheumatoid Arthritis Are Associated with Pain and Physical Function in Patients Treated with Tofacitinib: A Post-Hoc Analysis of Phase 3 Trials
Vibeke Strand¹, Rieke Alten², Jeffrey Kaine³, Arif Soonasra⁴, Christopher W Murray⁴, Haiyun Fan⁴, Christopher F Mojcik⁵ and Gene Wallenstein⁶, ¹Stanford University, Palo Alto, CA, ²Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³Sarasota Arthritis Research Center, Sarasota, FL, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We examined associations of pain and physical function with Patient…
Abstract Number: 1648 • 2016 ACR/ARHP Annual Meeting
Long-Term Clinical, Radiographic and Patient-Reported Outcomes Based on RAPID3 Responses with Tofacitinib at 6 Months
Vibeke Strand¹, Martin J Bergman², Eun Bong Lee³, Yusuf Yazici⁴, Bethanie Wilkinson⁵, Liza Takiya⁶, Gene Wallenstein⁵, Chuanbo Zang⁷ and Eustratios Bananis⁷, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Taylor Hospital, Ridley Park, PA, ³Seoul National University, Seoul, Korea, Republic of, ⁴New York University, Hospital of Joint Diseases, New York, NY, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. RAPID3 (Routine Assessment of Patient [Pt] Index Data 3) is a pooled…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].